Edgewise Therapeutics, Inc. (EWTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Boulder, CO, United States. Le PDG actuel est Kevin Koch.
EWTX a date d'introduction en bourse 2021-03-26, 117 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.62B.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases, particularly rare genetic muscle disorders. The company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, and has completed Phase 1 clinical trials. Edgewise is building a pipeline of precision medicine candidates that target key muscle proteins and modulators to treat genetically defined muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company is advancing innovative therapeutic approaches for patients with serious muscle-wasting conditions.
